Background: HER-2/neu overexpression appears to be associated with improved response to anthracycline-based chemotherapy, but its association with response to taxane-based chemotherapy is unclear. In this retrospective subset analysis of patients with metastatic breast cancer enrolled in a randomized treatment trial, we investigated the response of patients with known HER-2/neu status to treatment with taxane-based epirubicin-paclitaxel (ET) chemotherapy compared with treatment with epirubicin-cyclophosphamide (EC) chemotherapy. Methods: HER-2/neu status (positive [i.e., HER-2/neu amplification] or negative [i.e., no HER-2/ neu amplification]) of archival specimens of primary tumors from 297 patients with metastatic breast cancer was determined by use of fluorescence in situ hybridization. Associations between HER-2/neu status and the efficacy of randomly assigned chemotherapy (ET versus EC) were investigated. All statistical tests were two-sided. Results: Patients with HER-2/neu-positive tumors had a statistically significantly greater objective response rate than patients with HER-2/neu-negative tumors to treatment with ET (76% versus 50%, respectively; P ‫؍‬ .005) but not to treatment with EC (46% versus 33%; P ‫؍‬ .130). The objective response rate associated with ET was greater than that associated with EC for both HER-2/neu-positive tumors (76% versus 46%; P ‫؍‬ .004) and HER-2/neu-negative tumors (50% versus 33%; P ‫؍‬ .002). However, the improvement in the objective response rate associated with ET, compared with that associated with EC, was greater for patients with HER-2/neu-positive tumors (adjusted odds ratio [OR] ‫؍‬ 3.64, 95% confidence interval [CI] ‫؍‬ 1.48 to 8.92; P ‫؍‬ .005) than for patients with HER-2/neu-negative tumors (adjusted OR ‫؍‬ 1.92, 95% CI ‫؍‬ 1.01 to 3.64; P ‫؍‬ .046).
Results from early clinical trials suggest that the unfavorable prognosis associated with HER-2/neu overexpression results, in part, from resistance to chemotherapy, especially to the combination regimen of cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) (4, 5) . However, recent reports comparing the efficacy of CMF in a treated group with that in an untreated control group have not supported this finding and have found instead that both patients with HER-2/neu-negative and HER-2/neu-positive tumors benefited from CMF treatment (6, 7) . Results from other studies indicate that patients with HER-2/neupositive tumors may receive more benefit from anthracyclinecontaining adjuvant regimens than from regimens not containing an anthracycline (8, 9) , but more recent clinical data indicate that the benefit from an anthracycline-based regimen is only marginally better than that from the CMF regimen (10) . Consequently, the question of whether HER-2/neu is a marker of chemotherapy resistance or sensitivity is still debated. In addition, little clinical information is available on the association between HER-2/neu status and response to taxane-based regimens. Preliminary results from smaller uncontrolled phase II studies in patients with metastatic breast cancer (11, 12) , investigating the interaction between HER-2/neu status and the response to treatment with paclitaxel or docetaxel (11) or with a combination of paclitaxel and doxorubicin (12) , showed better response rates in patients with HER-2/neu-positive tumors than in patients with HER-2/ neu-negative tumors. However, these studies do not provide insights on whether the increased response rates are a taxanespecific effect or whether a HER-2/neu-positive status is generally associated with improved response rates to cytotoxic agents.
Previous studies of the association between HER-2/neu status and the response to chemotherapy have been challenged because of the use of inappropriate control groups or inaccurate methods to detect the alteration of the HER-2/neu gene. To avoid such controversies, we analyzed HER-2/neu status in the present study with fluorescence in situ hybridization (FISH), as this method allows the most accurate detection of the HER-2/neu alteration in formalin-fixed paraffin-embedded tissue (13) (14) (15) . Furthermore, we studied the association between HER-2/neu amplification and response to a taxane in the context of a randomized controlled study investigating the use of a taxane in patients with metastatic breast cancer. This approach allowed us to assess the objective response rate (as a direct measure of chemosensitivity), progression-free survival, and overall survival and enabled us to separate taxane-specific effects from effects generally associated with chemotherapy. We obtained data for this retrospective subset analysis from a randomized trial of the Arbeitsgemeinschaft für Gynäkologische Onkologie (AGO) that compared an epirubicin-cyclophosphamide (EC) regimen with an epirubicin-paclitaxel (ET) regimen as first-line therapies for patients with metastatic breast cancer. Preliminary findings from the first analysis of 429 patients, which were reported previously (16) , indicated that the two treatment arms were not demonstrably different in terms of overall efficacy, with comparable objective response rates for ET and EC (46% and 41%, respectively) and comparable median progression-free survivals for both ET and EC (39 and 33 weeks, respectively; P ϭ .089) (16) . In this retrospective subset analysis, we investigated whether HER-2/neu amplification is associated with an improved response to a taxane-based ET regimen compared with an EC regimen.
PATIENTS AND METHODS
The study group consisted of patients with metastatic breast cancer enrolled between October 1, 1996, and December 31, 1999, in a prospective randomized multicenter trial of the AGO (16) . For the original study, 579 patients were recruited from 71 centers in Germany. Twenty (3.4%) of these 579 patients enrolled from noncompliant participating centers were excluded from the analysis. Of the 559 remaining patients, 34 (6.1%) did not meet the eligibility criteria (first detected at in-house monitoring sessions) because of nonmeasurable disease at randomization (n ϭ 13), concomitant other therapy (n ϭ 8), or other reasons (n ϭ 10). Of these 559 patients, 516 patients were enrolled in active treatment arms and had received at least one cycle of chemotherapy. All women aged 18 -75 years had evidence of progressive, radiographically assessable, metastatic breast cancer and had not received prior chemotherapy for metastatic disease. Only one preceding hormonal therapy was allowed for treatment of metastatic breast cancer before study entry (i.e., tamoxifen). All patients were required to have a Karnofsky performance status of more than 60%, a life expectancy of 3 months or more, normal serum calcium levels, and normal cardiac, renal, hepatic, pulmonary, hematologic, and coagulation functions. Patients were excluded for active infections, pregnancy or lactation, clinically significant cardiac disease, known hemorrhagic diseases, metastasis to the central nervous system, metastasis to bone only, prior treatment with epirubicin at a dose of more than 400 mg/m 2 of body surface area, or concomitant use of any investigational agent. After stratification (no hormonal therapy versus one preceding hormonal therapy for treatment of metastatic breast cancer), patients were randomly assigned to receive either epirubicin (60 mg/m 2 ) and cyclophosphamide (600 mg/m 2 ) or epirubicin (60 mg/m 2 ) and paclitaxel (175 mg/m 2 ) over a 3-hour period for a maximum of 10 cycles-with each combination therapy given once every 3 weeks. No further treatment was allowed in the protocol without documented evidence of treatment failure. All patients signed a written internal review board-approved informed consent document before study entry. Tumor samples and clinical information were obtained under institutional review board approval; this study is a retrospective statistical analysis of results obtained from the AGO study.
Before entry into the study, all patients underwent a complete physical examination, chest x-rays, an ultrasonographic examination of the liver, and a bone scan. Computed tomography examinations of the chest and abdomen were performed when clinically indicated. Response was determined at 12-week intervals. A complete response was defined as the disappearance of all radiographically and/or visually apparent tumor tissue. A partial response was defined as a greater than 50% decrease (two-dimensional measurements) of all measurable lesions. Disease progression was defined as a greater than 25% increase in any measurable lesion or the appearance of any new lesion. Objective responses were not routinely confirmed by a later evaluation. The objective response rate was defined as the percentage of patients achieving a complete or partial response. Progression-free survival was defined as the time from the date of randomization to the date of documented disease progression. The occurrence of a secondary malignancy or death from any cause was also considered to be disease progression. Overall survival was defined as the time from the date of randomization to the date of death from any cause or to the date of loss to follow-up.
Specimens
Archived primary tumor specimens from all 516 patients were requested from 71 institutions participating in the randomized AGO study of first-line treatment for patients with metastatic breast cancer. However, because the primary surgery was often performed at institutions other than those participating in the clinical AGO trial, tissue blocks of primary breast cancer biopsy samples were available for HER-2/neu analysis from 297 (58%) of the 516 patients. Each tissue block was sectioned for histologic analysis, and five blocks lacking residual invasive carcinoma were omitted, leaving a total of 292 samples. Of these 292 samples, 275 (94%) were technically satisfactory for analysis of HER-2/neu gene amplification.
HER-2/neu Analysis
HER-2/neu gene copy number was analyzed by use of FISH on 4-m sections of paraffin-embedded and formalinfixed tumor tissue. Specimen preparation, hybridization, and microscopy were performed as previously described (14) . A SpectrumOrange-labeled HER-2/neu probe (Vysis, Downers Grove, IL) was used to determine gene copy number (number of gene signals per cell). In addition, to account for increased HER-2/neu gene copy number because of chromosome 17 polysomy (increased copy number of the entire chromosome, which is frequently seen in breast cancer), we also hybridized specimens with a probe for the chromosome 17 centromere labeled with the SpectrumGreen fluorochrome (PathVision 30-161060; Vysis). Data were expressed as the number of HER-2/neu genes per chromosome 17 centromere; we used two HER-2/neu genes per chromosome 17 centromere as the biological cutoff to distinguish tumors with and without HER-2/neu amplification, respectively (14) .
FISH Scoring Criteria
FISH scores were analyzed as previously described (14) . In brief, slides were initially scanned for the HER-2/neu signals and sorted into the following three groups: 1) tumors with obvious gene amplification (i.e., signal clusters of more than 10 -15 signals per cell), 2) tumors readily classified as single copy (i.e., no cells with more than four HER-2/neu signals detectable), and 3) an intermediate group with low-level copy number increases. In the intermediate group, 100 randomly selected nuclei were scored for both HER-2/neu and chromosome 17 centromere signals, and HER-2/neu amplification was defined as the mean ratio of the number of HER-2/neu signals to the number of chromosome 17 centromere signals. Tumors with a ratio of more than 2 were classified as HER-2/neu positive, and tumors with a ratio of 2 or less were classified as HER-2/neu negative.
Statistical Analysis
Baseline prognostic and patient characteristics between the 275 patients with FISH data available and the 241 patients without such data were compared by use of the chi-square test to exclude the possibility of selection bias. Baseline prognostic and patient characteristics were also compared between treatment groups (ET and EC) for patients with a known HER-2/neu status by use of the chi-square test. We explored associations between the frequency of HER-2/neu gene amplification, prognostic factors, and patient characteristics, including age, histology (ductal, lobular, or other), nuclear grade (1, 2, or 3), estrogen or progesterone receptor status of tumor, location of metastases (liver, lung, or other), number of metastatic sites (1, 2, or Ն3), and whether prior palliative hormonal therapy or prior adjuvant chemotherapy was received. The association of HER-2/neu gene amplification with each of these characteristics was tested individually by use of the chi-square test. The prognostic relevance of baseline factors for progression-free survival and overall survival was assessed with a univariate Cox model.
To determine whether HER-2/neu gene amplification was associated with therapeutic efficacy, we calculated objective response rates for both treatment regimens and patient subsets according to HER-2/neu status. Progression-free survival and overall survival were estimated with the Kaplan-Meier method. Of the 275 patients with evaluable FISH results, 258 (94%) had radiographically measurable disease at a later evaluation, and information on progression-free survival and overall survival was available for all 275 patients. Progression-free survival and overall survival were compared by using the log-rank test. We estimated the odds ratio (OR) for the objective response rate and the relative risks (RRs) for progression-free survival and overall survival by use of a Cox univariate model. In multivariable analysis, a logistic regression model (objective response rate) and a Cox proportional hazard regression model (progressionfree survival and overall survival; the assumptions of proportionality for the Cox regression were verified by residuals plots. Martingale [or deviance] residuals were plotted against survival time or covariates. For logistic regression, goodness-of-fit statistics was used for model checking) were used to investigate associations between the probability of response and age, histology (ductal, lobular, or other), localization of metastasis (liver, lung, or other), number of metastatic sites (1, 2, or Ն3), whether palliative endocrine therapy or adjuvant chemotherapy had been received, nuclear grade (1, 2, or 3), and estrogen and progesterone receptor status determined at the primary diagnosis. A stepwise procedure was used for covariate selection. All statistical tests were two-sided. Data from patients whose tumors were HER-2/neu negative and patients whose tumors were HER-2/neu positive were tested for equality by adding an interaction term to the logistic regression or the Cox proportional hazards model and by testing its statistical significance with the Wald test.
RESULTS

Characterization of Study Cohort
Comparison of characteristics of the cohort of eligible patients with and without known HER-2/neu status detected no statistically significant differences between the group whose HER-2/neu status was known and the group whose HER-2/neu status was unknown ( Table 1 ), indicating that our study sample was representative of the overall patient population. Among the 275 patients whose HER-2/neu status could be determined, 137 had been randomly assigned to receive EC and 138 had been randomly assigned to receive ET (Table 2 ). Patients in both treatment groups received a median of six cycles of chemotherapy. As indicated in Table 2 , patient and disease characteristics were well balanced across the two treatment arms. Of the 275 evaluable primary tumor specimens, HER-2/neu gene amplification was detected in 97 (35%) tumors, 48 from the EC arm and 49 from the ET arm. The prognostic relevance of baseline factors for progression-free survival and overall survival for patients with known HER-2/neu status is shown in Table 3 .
Association Between HER-2/neu and Baseline Characteristics
HER-2/neu amplification was inversely associated with estrogen receptor status, in that 46 (52%) of the 89 HER-2/neupositive tumors were classified as estrogen receptor positive and 110 (67%) of the 163 HER-2/neu-negative tumors were classified as estrogen receptor positive (P ϭ .014). HER-2/neu amplification was also positively associated with a higher proportion of patients who had received prior adjuvant chemotherapy, in that 48 (49%) of the 97 patients with HER-2/neu-positive tumors had received adjuvant chemotherapy compared with 52 (30%) of the 175 patients with HER-2/neu-negative tumors (P ϭ .001). HER-2/neu gene amplification, however, was not associated with the progesterone receptor status, number or site of metastatic lesions, the type of histology, the nuclear grade of the primary tumor, patient age, or the application of a prior palliative hormone therapy (data not shown).
Association Between HER-2/neu Status and Treatment Outcome
We initially investigated whether HER-2/neu amplification was associated with treatment outcomes in the entire study cohort of 275 patients. Patients with HER-2/neu-positive tumors had a statistically significantly higher objective response rate (60% [95% CI ϭ 51% to 70%] versus 41% [95 CI ϭ 34% to 49%]; 2 P ϭ .004; logistic regression OR ϭ 2.19 [95% CI ϭ 1.31 to 3.65]; P ϭ .003) than patients with HER-2/neu-negative tumors. Despite an increased primary response, patients with HER-2/neu-positive tumors, however, had a poorer prognosis than patients with HER-2/neu-negative tumors. Statistically significantly shorter progression-free survival was observed among the 97 patients with HER-2/neu-positive tumors (median progression-free survival ϭ 8.4 months, 95% CI ϭ 7.3 to 10.3 months) than among the 178 patients with HER-2/neu-negative tumors (median progression-free survival ϭ 10.3 months, 95% CI ϭ 7.6 to 11.7 months) (P ϭ .020). In addition, statistically significantly shorter overall survival was observed among the 97 patients with HER-2/neu-positive tumors (median overall survival ϭ 19.0 months, 95% CI ϭ 15.1 to 22.1 months) than among the 178 patients with HER-2/neu-negative tumors (28.4 months, 95% CI ϭ 20.9 to 35.2 months) (P ϭ .023).
We next investigated the association between HER-2/neu status and treatment outcome separately for patients treated with EC and for patients treated with ET. Among those treated with EC, patients with HER-2/neu-positive tumors and HER-2/ neu-negative tumors had comparable objective response rates (46% [95% CI ϭ 32% to 60%] versus 33% [95% CI ϭ 22% to 43%]; P ϭ .130; Fig. 1 ). However, patients with HER-2/ neu-positive tumors had statistically significantly shorter progression-free survival (median progression-free survival ϭ 7.1 months, 95% CI ϭ 4.1 to 9.3 months) than patients with HER-2/neu-negative tumors (median progression-free survival ϭ 10.4 months, 95% CI ϭ 6.9 to 14.9 months) (P ϭ .010) (Fig.  2, A) . Likewise, patients with HER-2/neu-positive tumors had statistically significantly shorter overall survival (median overall survival ϭ 16.4 months, 95% CI ϭ 12.1 to 20.1 months) than patients with HER-2/neu-negative tumors (median overall survival ϭ 33.1 months, 95% CI ϭ 20.9 to 50.6 months) (P ϭ .010) (Fig. 2, C) .
In contrast, among patients treated with ET, patients with HER-2/neu-positive tumors had a statistically significantly higher objective response rate (76% [95% CI ϭ 63% to 88%]) than patients with HER-2/neu-negative tumors (50% [95% CI ϭ 39% to 61%]; P ϭ .005; Fig. 1 ). Progression-free survival of patients with HER-2/neu-positive tumors (median progressionfree survival ϭ 10.5 months, 95% CI ϭ 8.1 to 11.9 months) was similar to that of patients with HER-2/neu-negative tumors (median progression-free survival ϭ 9.6 months, 95% CI ϭ 7.5 to 11.3 months) (P ϭ .584) (Fig. 2, B) . Overall survival of patients with HER-2/neu-positive tumors (median overall survival ϭ 21.4 months, 95% CI ϭ 15.3 to 27.3 months) was similar to that of patients with HER-2/neu-negative tumors (median overall survival ϭ 27.5 months, 95% CI ϭ 17.1 to 35.2 months) (P ϭ .463) (Fig. 2, D) .
Association Between HER-2/neu Status and Response to Paclitaxel
The central hypothesis tested in the present study was whether the ET regimen is more effective than the EC regimen among patients with HER-2/neu-positive tumors than in patients with HER-2/neu-negative tumors. We found that the objective response rate associated with the ET regimen was better than that associated with the EC regimen among patients with HER-2/neu-positive tumors (76% [95% CI ϭ 63% to 88%] versus 46% [95% CI ϭ 32% to 60%]; P ϭ .004) and among patients with HER-2/neu-negative tumors (50% [95% CI ϭ 39% to 61%] versus 33% [95% CI ϭ 22% to 43%]; P ϭ .002; Fig. 1) . The difference in objective response rates associated with the ET and EC regimens, however, was greater for patients with HER-2/neu-positive tumors (adjusted OR ϭ 3.64, 95% CI ϭ 1.48 to 8.92; P ϭ .005) than for patients with HER-2/neu-negative tumors (adjusted OR ϭ 1.92, 95% CI ϭ 1.01 to 3.64; P ϭ .046) ( Table 4) .
Furthermore, in patients with HER-2/neu-positive tumors, longer progression-free survival (median progression-free survival ϭ 10.5 months [95% CI ϭ 8.1 to 11.9 months] versus 7.1 months [95% CI ϭ 4.1 to 9.3 months]; P ϭ .116) (Fig. 3, B) (Fig. 3, D) were associated with the ET regimen than with the EC regimen, although these differences were not statistically significant. After adjusting for the effects of other statistically significant prognostic variables in a multivariable analysis (such as localization of metastases, number of sites, estrogen receptor status, and prior adjuvant chemotherapy), the relative risk of failure for the ET regimen compared with that for the EC regimen in patients with HER-2/neu-positive tumors was 0.65 for progression-free survival (95% CI ϭ 0.42 to 1.02; P ϭ.062) and 0.60 for overall survival were treated with epirubicin-cyclophosphamide (EC) showed an objective response rate that was similar to that of HER-2/neu-negative patients (46% versus 33%; P ϭ .130). In contrast, patients with HER-2/neu-positive tumors who were treated with epirubicin-paclitaxel (ET) showed a statistically significantly higher objective response rate than patients with HER-2/neu-negative tumors (76% versus 50%; P ϭ .005). ET, compared with EC, was associated with a higher objective response rate in both patients with HER-2/neu-positive tumors (76% versus 46%; P ϭ .004) and patients with HER-2/neu-negative tumors (50% versus 33%; P ϭ .002). However, after adjustment, the difference in response associated with ET, compared with that associated with EC, was greater in patients with HER-2/neu-positive tumors (odds ratio [OR] ϭ 3.64, 95% confidence interval [CI] ϭ 1.48 to 8.92; P ϭ .005) than in patients with HER-2/neu-negative tumors (OR ϭ 1.92, 95% CI ϭ 1.01 to 3.64; P ϭ .046) (see Table 4 ). Objective response rates were calculated for both treatment regimens and patient subsets according to HER-2/neu status. Error bars ϭ 95% confidence intervals; solid bars ϭ ET; open bars ϭ EC. All statistical tests were two-sided. (95% CI ϭ 0.36 to 1.02; P ϭ .059) (Table 4) , where a relative risk greater than 1 favors the EC regimen and a relative risk less than 1 favors the ET regimen. Among patients with HER-2/neunegative tumors, both progression-free survival (median progression-free survival ϭ 9.6 months [95% CI ϭ 7.5 to 11.3 months] versus 10.4 months [95% CI ϭ 6.9 to 14.9 months]; P ϭ .350) (Fig. 3, A) and overall survival (median overall survival ϭ 27.5 months [95% CI ϭ 17.1 to 35.2 months] versus 33.1 months [95% CI ϭ 20.9 to 50.6 months]; P ϭ .292) (Fig.  3, C) were similar for patients treated with the EC regimen and for patients treated with the ET regimen. The adjusted relative risk of failure for the ET regimen compared with that for the EC regimen in patients with HER-2/neu-negative patients was 1.10 for progression-free survival (95% CI ϭ 0.77 to 1.57; P ϭ .590) and 1.10 for overall survival (95% CI ϭ 0.70 to 1.72; P ϭ .680). Statistical tests for the interaction between treatment and HER-2/neu status were suggestive of such interactions but were not statistically significant (objective response rate, unadjusted P for interaction ϭ .308 and adjusted P ϭ .256; progression-free survival, unadjusted P ϭ .090 and adjusted P ϭ .109; overall survival, unadjusted P ϭ .152 and adjusted P ϭ .136; Table 4 and Fig. 4 ).
DISCUSSION
In this study, we found that patients with HER-2/neupositive tumors had a better response to first-line chemother- apy than patients with HER-2/neu-negative tumors. However, when we used progression-free survival or overall survival as end points for treatment outcome, the poorer prognosis for patients with HER-2/neu-positive tumors, compared with patients with HER-2/neu-negative tumors, did not appear to concur with sensitivity toward chemotherapy. A possible explanation for this discordance could be based on the observation that tumor cells with HER-2/neu overexpression proliferate more rapidly than HER-2/neu-negative cells (17, 18) , so that patients with HER-2/neu-positive tumors might relapse sooner (unless their tumors are completely eradicated) than patients with HER-2/neu-negative tumors. As previously described, HER-2/neu overexpression results in increased cell proliferation in preclinical xenograft models, and this increased proliferation can lead to a more rapid recovery from the cytotoxic effects of chemotherapeutic agents, despite the tumor's initial chemosensitivity (17) (18) (19) (20) . Our results from this clinical study confirm these preclinical results; i.e., patients with HER-2/neu-positive tumors relapsed more quickly after chemotherapy than patients with HER-2/neu-negative tumors, despite the higher initial response rate in patients with HER-2/neu-positive tumors.
Although patients with HER-2/neu-positive tumors have a poor prognosis, our results underscore the fact that HER-2/neu amplification is not an intrinsic marker of chemoresistance to either the EC regimen or the ET regimen. When response rates of patients with HER-2/neu-positive and patients with HER-2/ neu-negative tumors were compared separately by treatment arm, chemotherapeutic sensitivity in patients with HER-2/neupositive tumors, compared with patients with HER-2/neu-negative tumors, appeared to be particularly pronounced after treatment with the ET regimen. Among patients treated with the ET regimen, but not among those treated with the EC regimen, HER-2/neu amplification was statistically significantly associated with improved response rates. These findings support the following two hypotheses: 1) that a HER-2/neu-positive status does not appear to confer unique clinical chemoresistance to the EC or ET regimen and 2) that patients with HER-2/neu-positive tumors might be particularly sensitive to the paclitaxelcontaining regimen.
For further validation, we compared the outcomes after treatment with the ET regimen and after the EC regimen separately in patients with HER-2/neu-positive tumors and in patients with HER-2/neu-negative tumors. In patients with HER-2/neu-positive tumors, substitution of paclitaxel for cyclophosphamide resulted in a statistically significantly increased objective response rate (adjusted OR ϭ 3.64, 95% CI ϭ 1.48 to 8.92; P ϭ .005), which was more pronounced than the increase observed in HER-2/neu-negative patients (adjusted OR ϭ 1.92, 95% CI ϭ 1.01 to 3.64; P ϭ .046). We also found evidence for better progression-free survival and better overall survival after treatment with the ET regimen than after treatment with the EC regimen in patients with HER-2/neu-positive tumors than in patients with HER-2/neu-negative tumors. Although these differences in progression-free survival and overall survival did not reach statistical significance, they may be clinically meaningful because the relative risk for disease progression associated with the ET regimen, compared with that of the EC regimen, was reduced by 35% (adjusted RR ϭ 0.65, 95% CI ϭ 0.42 to 1.02; P ϭ.062), but not statistically significantly so. However, we believe that this association should be studied further in a larger study with more statistical power. Similar evidence of an improved overall survival after treatment with the ET regimen among patients with HER-2/neu-positive tumors was also observed (adjusted RR ϭ 0.60, 95% CI ϭ 0.36 to 1.02; P ϭ .059), which is remarkable in view of the fact that many of the patients had received taxane-based second-line chemotherapy after EC treatment failure. Although we could not confirm a statistically significant interaction between treatment and HER-2/neu status, the data are suggestive for such an interaction for progressionfree survival (P ϭ .109) and for overall survival (P ϭ .136). The estimated power for detecting a statistically significant interaction in the present study cohort, however, was only 40% for progression-free survival and 25% for overall survival; thus, this study was not large enough to allow meaningful interaction studies between treatment and HER-2/neu status. ‫ء‬Univariate analyses estimate the odds ratios (ORs) for the objective response rate and the relative risks (RRs) for progression-free survival and overall survival by use of a Cox univariate model. CI ϭ confidence interval. Adjusted multivariable analyses control for the potential effects of age, histology, site of metastasis, number of metastatic sites, nuclear grade, estrogen receptor status, prior palliative hormone therapy, and prior adjuvant chemotherapy. A logistic regression model was used for response evaluation, and a Cox proportional hazards regression model was used for evaluation of progression-free survival and overall survival. A stepwise procedure was used for covariate selection. For the adjusted odds ratio, prior chemotherapy was the only factor to be controlled in the logistic model when comparing epirubicin-paclitaxel (ET) with epirubicin-cyclophosphonide (EC) because other factors, such as age, grade, histology type, and estrogen receptor status, didn't show statistically significant associations with response. For the adjusted relative risks, estrogen receptor status, prior chemotherapy, liver metastasis, and number of metastases (Ͻ3 sites or Ն3 sites) were the prognostic factors included in the Cox model to be controlled while comparing ET with EC. Other factors did not show statistically significant association with recurrence and/or survival and therefore were not included in the model. †Treatment odds ratio and relative risks for patients whose tumors were HER-2/neu negative and those whose tumors were HER-2/neu positive were tested for equality by adding an interaction term to the logistic regression or Cox proportional hazards model and by testing its statistical significance with the two-sided Wald test.
Previous studies reported higher response rates after taxanebased therapies for patients with HER-2/neu-positive tumors than for patients with HER-2/neu-negative tumors (11, 12) . However, these earlier studies did not have appropriate control cohorts that would allow separate analyses of taxane-specific treatment effects and of general treatment effects associated with chemotherapy. A more recent study conducted by the Breast Cancer International Research Group (BCIRG) provides more comprehensive data in support of our findings. The BCIRG Study 001, in which 1491 patients with lymph node-positive primary breast cancer were randomly assigned to an adjuvant chemotherapy regimen of docetaxel-doxorubicin-cyclophosphamide or a regimen of fluorouracil-doxorubicin-cyclophosphamide, provided an important control group to investigate taxane-specific effects. Results of the first analysis of this study are consistent with our results because they indicate that a better outcome was associated with the docetaxel-doxorubicin-cyclophosphamide regimen than with the fluorouracil-doxorubicincyclophosphamide regimen, especially among patients with HER-2/neu-positive tumors (for disease-free survival, hazard Experimental results regarding HER-2/neu overexpression and the response to taxane-based regimens are contradictory, with some investigators reporting unique resistance to such regimens (22, 23) and others reporting the lack of such resistance (17) . In a previous study investigating the association of HER-2/neu overexpression with taxane sensitivity, we stably transfected six human breast and ovarian cancer cell lines with a full-length human HER-2/neu cDNA (17) to directly compare drug sensitivity in parent and daughter cells that differed genetically because one member of the pair overexpressed the human HER-2/neu gene. In three of six human breast or ovarian cancer cell lines, HER-2/neu overexpression resulted in a statistically significantly increased sensitivity toward paclitaxel; this result led us to conclude that HER-2/neu overexpression was most likely not associated with in vitro resistance to paclitaxel (17) .
Previous results indicated an interaction between HER-2/neu overexpression and the dose of an anthracycline-based combination chemotherapy (24) , in which a statistically significantly better outcome was found for patients with HER-2/neu-positive primary breast cancer treated with standard doses of fluorouracil-doxorubicin-cyclophosphamide than for patients treated with lower doses of these drugs. In our study, however, the ET and EC regimens were given at standard doses, indicating that the observed treatment outcomes most likely did not result from an interaction between HER-2/neu amplification and the dose level of chemotherapeutic agents.
Because preceding adjuvant chemotherapy reduces the response to first-line chemotherapy, it is noteworthy that patients with HER-2/neu-positive tumors (who received more adjuvant chemotherapy than patients with HER-2/neu-negative tumors) still responded better than patients with HER-2/neu-negative tumors to first-line chemotherapy for metastatic breast cancer. However, exposure to an anthracycline-based adjuvant chemotherapy might increase sensitivity of metastatic cancer to a non-cross-resistant taxane-containing regimen and lead to a better response to the ET regimen than to the EC regimen. Nevertheless, the independence of the observed treatment effects from other potentially confounding variables in multivariable analysis (such as a negative estrogen receptor status, localization and number of metastatic sites, or the prior application of adjuvant chemotherapy) does strengthen our hypothesis that HER-2/neu amplification might be associated with increased response to taxane-based first-line chemotherapy.
The results of the present study, nonetheless, should be interpreted cautiously because the study was based on a retrospective subgroup analysis whose objective was not part of the original randomized study. Although our results are not yet useful for determining the best treatment for patients with metastatic breast cancer, they do suggest that there may be an interesting biological question regarding the role of HER-2/neu and response to treatment with a taxane-based regimen. The best way to evaluate the association between treatment and HER-2/ neu status would be a prospective controlled study; however, it is unlikely that such a study could be conducted now because chemotherapy alone as a first-line treatment has been replaced with a combination of chemotherapy and trastuzumab, which is associated with a statistically significant survival advantage for patients with HER-2/neu-positive metastatic breast cancer (25) . Therefore, confirmatory studies including sufficiently powered retrospective analysis are needed and would be of great interest to those for whom the efficacy of taxane-based regimens is currently a matter of debate. Fig. 4 . Association between objective response rates (ORRs), progression-free survival (PFS), or overall survival (OS) and treatment according to HER-2/neu status. Data for the objective response rate were adjusted (by use of the logistic model) for prior adjuvant chemotherapy. Relative risks (RRs) of failure were adjusted (by use of the Cox model) for localization of metastasis (liver, lung, or other), number of metastatic sites (1, 2, or Ն3), estrogen receptor status, and prior adjuvant chemotherapy. Bars ϭ 95% confidence intervals. All statistical tests were two-sided.
